Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin analogs

J. Pinski, S. Milovanovic, T. Yano, A. Hamaoui, S. Radulovic, R. Z. Cai, Andrew V Schally

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Several somatostatin analogs with recently synthesized acetylated N terminus were assayed in vivo for their effects on sodium pentobarbital- stimulated growth hormone (GH) levels in fed male rats and gastrin-releasing peptide (14-27)-stimulated gastrin levels in fasted male rats. The binding characteristics of these analogs to somatostatin receptors were also examined in various human tumors and normal tissues. The analog RC-101-I, injected at a dose of 0.1 μg/100 g body wt, significantly suppressed GH release (P < 0.01) for at least 2 hr. Analog RC-160-II caused the longest inhibition of GH release, greater than that induced by nonacetylated parent analog RC-160, with GH levels showing significant suppression (P < 0.01) for more than 3 hr. Analogs RC-160-II and RC-101-I and RC-160, injected at a dose of 1.0 μg/100 g body wt, significantly (P < 0.01) suppressed gastrin-releasing peptide (14- 27)-stimulated serum gastrin. Analog RC-101-I was active in this test at a dose of 0.1 μg/100 g body wt. RC-160-II showed significant binding to somatostatin-14 receptors in all investigated tissues (human colon, human colon cancer, breast cancer, human pancreas and pancreatic cancer, human prostate and prostate cancer, and rat cerebral cortex), but there were marked variations in binding affinities among various normal and cancerous tissues. The highest affinity was found in membranes of colon cancer (K(a) = 18.4 nM- 1) and breast cancer (K(a) = 12.46 nM-1). The binding affinity of RC-160- II to somatostatin receptors in membranes of the breast cancer was similar to that of RC-160. RC-101-I showed higher binding affinity to somatostatin-14 receptors than RC-160 in human breast, pancreatic, and prostate cancer. With the exception of breast cancer tissue, the binding affinity of RC-101-I was significantly lower than that of RC-160-II in membranes of all investigated tissues. It can be concluded that acetylated somatostatin analogs RC-101-I and RC-160-II possess prolonged and enhanced biological activities in suppressing serum GH and gastrin in rats. Significant variations in binding affinities for these analogs in different tissues and various tumors suggest that differences may exist between somatostatin receptors in normal versus malignant tissues. This raises the possibility that some of these analogs could be used more selectively in the treatment of various neoplasms.

Original languageEnglish
Pages (from-to)49-56
Number of pages8
JournalProceedings of the Society for Experimental Biology and Medicine
Volume200
Issue number1
StatePublished - May 21 1992
Externally publishedYes

Fingerprint

Bioactivity
Somatostatin
Tumors
Somatostatin Receptors
Tissue
Growth Hormone
Neoplasms
Breast Neoplasms
Pancreatic Neoplasms
Rats
Gastrins
Prostatic Neoplasms
Membranes
Colonic Neoplasms
vapreotide
Pentobarbital
Serum
Cerebral Cortex
RC 101
Colon

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin analogs. / Pinski, J.; Milovanovic, S.; Yano, T.; Hamaoui, A.; Radulovic, S.; Cai, R. Z.; Schally, Andrew V.

In: Proceedings of the Society for Experimental Biology and Medicine, Vol. 200, No. 1, 21.05.1992, p. 49-56.

Research output: Contribution to journalArticle

@article{68b14fa308f347af97ecbd93a4ecd74a,
title = "Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin analogs",
abstract = "Several somatostatin analogs with recently synthesized acetylated N terminus were assayed in vivo for their effects on sodium pentobarbital- stimulated growth hormone (GH) levels in fed male rats and gastrin-releasing peptide (14-27)-stimulated gastrin levels in fasted male rats. The binding characteristics of these analogs to somatostatin receptors were also examined in various human tumors and normal tissues. The analog RC-101-I, injected at a dose of 0.1 μg/100 g body wt, significantly suppressed GH release (P < 0.01) for at least 2 hr. Analog RC-160-II caused the longest inhibition of GH release, greater than that induced by nonacetylated parent analog RC-160, with GH levels showing significant suppression (P < 0.01) for more than 3 hr. Analogs RC-160-II and RC-101-I and RC-160, injected at a dose of 1.0 μg/100 g body wt, significantly (P < 0.01) suppressed gastrin-releasing peptide (14- 27)-stimulated serum gastrin. Analog RC-101-I was active in this test at a dose of 0.1 μg/100 g body wt. RC-160-II showed significant binding to somatostatin-14 receptors in all investigated tissues (human colon, human colon cancer, breast cancer, human pancreas and pancreatic cancer, human prostate and prostate cancer, and rat cerebral cortex), but there were marked variations in binding affinities among various normal and cancerous tissues. The highest affinity was found in membranes of colon cancer (K(a) = 18.4 nM- 1) and breast cancer (K(a) = 12.46 nM-1). The binding affinity of RC-160- II to somatostatin receptors in membranes of the breast cancer was similar to that of RC-160. RC-101-I showed higher binding affinity to somatostatin-14 receptors than RC-160 in human breast, pancreatic, and prostate cancer. With the exception of breast cancer tissue, the binding affinity of RC-101-I was significantly lower than that of RC-160-II in membranes of all investigated tissues. It can be concluded that acetylated somatostatin analogs RC-101-I and RC-160-II possess prolonged and enhanced biological activities in suppressing serum GH and gastrin in rats. Significant variations in binding affinities for these analogs in different tissues and various tumors suggest that differences may exist between somatostatin receptors in normal versus malignant tissues. This raises the possibility that some of these analogs could be used more selectively in the treatment of various neoplasms.",
author = "J. Pinski and S. Milovanovic and T. Yano and A. Hamaoui and S. Radulovic and Cai, {R. Z.} and Schally, {Andrew V}",
year = "1992",
month = "5",
day = "21",
language = "English",
volume = "200",
pages = "49--56",
journal = "Experimental Biology and Medicine",
issn = "0037-9727",
publisher = "Society for Experimental Biology and Medicine",
number = "1",

}

TY - JOUR

T1 - Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin analogs

AU - Pinski, J.

AU - Milovanovic, S.

AU - Yano, T.

AU - Hamaoui, A.

AU - Radulovic, S.

AU - Cai, R. Z.

AU - Schally, Andrew V

PY - 1992/5/21

Y1 - 1992/5/21

N2 - Several somatostatin analogs with recently synthesized acetylated N terminus were assayed in vivo for their effects on sodium pentobarbital- stimulated growth hormone (GH) levels in fed male rats and gastrin-releasing peptide (14-27)-stimulated gastrin levels in fasted male rats. The binding characteristics of these analogs to somatostatin receptors were also examined in various human tumors and normal tissues. The analog RC-101-I, injected at a dose of 0.1 μg/100 g body wt, significantly suppressed GH release (P < 0.01) for at least 2 hr. Analog RC-160-II caused the longest inhibition of GH release, greater than that induced by nonacetylated parent analog RC-160, with GH levels showing significant suppression (P < 0.01) for more than 3 hr. Analogs RC-160-II and RC-101-I and RC-160, injected at a dose of 1.0 μg/100 g body wt, significantly (P < 0.01) suppressed gastrin-releasing peptide (14- 27)-stimulated serum gastrin. Analog RC-101-I was active in this test at a dose of 0.1 μg/100 g body wt. RC-160-II showed significant binding to somatostatin-14 receptors in all investigated tissues (human colon, human colon cancer, breast cancer, human pancreas and pancreatic cancer, human prostate and prostate cancer, and rat cerebral cortex), but there were marked variations in binding affinities among various normal and cancerous tissues. The highest affinity was found in membranes of colon cancer (K(a) = 18.4 nM- 1) and breast cancer (K(a) = 12.46 nM-1). The binding affinity of RC-160- II to somatostatin receptors in membranes of the breast cancer was similar to that of RC-160. RC-101-I showed higher binding affinity to somatostatin-14 receptors than RC-160 in human breast, pancreatic, and prostate cancer. With the exception of breast cancer tissue, the binding affinity of RC-101-I was significantly lower than that of RC-160-II in membranes of all investigated tissues. It can be concluded that acetylated somatostatin analogs RC-101-I and RC-160-II possess prolonged and enhanced biological activities in suppressing serum GH and gastrin in rats. Significant variations in binding affinities for these analogs in different tissues and various tumors suggest that differences may exist between somatostatin receptors in normal versus malignant tissues. This raises the possibility that some of these analogs could be used more selectively in the treatment of various neoplasms.

AB - Several somatostatin analogs with recently synthesized acetylated N terminus were assayed in vivo for their effects on sodium pentobarbital- stimulated growth hormone (GH) levels in fed male rats and gastrin-releasing peptide (14-27)-stimulated gastrin levels in fasted male rats. The binding characteristics of these analogs to somatostatin receptors were also examined in various human tumors and normal tissues. The analog RC-101-I, injected at a dose of 0.1 μg/100 g body wt, significantly suppressed GH release (P < 0.01) for at least 2 hr. Analog RC-160-II caused the longest inhibition of GH release, greater than that induced by nonacetylated parent analog RC-160, with GH levels showing significant suppression (P < 0.01) for more than 3 hr. Analogs RC-160-II and RC-101-I and RC-160, injected at a dose of 1.0 μg/100 g body wt, significantly (P < 0.01) suppressed gastrin-releasing peptide (14- 27)-stimulated serum gastrin. Analog RC-101-I was active in this test at a dose of 0.1 μg/100 g body wt. RC-160-II showed significant binding to somatostatin-14 receptors in all investigated tissues (human colon, human colon cancer, breast cancer, human pancreas and pancreatic cancer, human prostate and prostate cancer, and rat cerebral cortex), but there were marked variations in binding affinities among various normal and cancerous tissues. The highest affinity was found in membranes of colon cancer (K(a) = 18.4 nM- 1) and breast cancer (K(a) = 12.46 nM-1). The binding affinity of RC-160- II to somatostatin receptors in membranes of the breast cancer was similar to that of RC-160. RC-101-I showed higher binding affinity to somatostatin-14 receptors than RC-160 in human breast, pancreatic, and prostate cancer. With the exception of breast cancer tissue, the binding affinity of RC-101-I was significantly lower than that of RC-160-II in membranes of all investigated tissues. It can be concluded that acetylated somatostatin analogs RC-101-I and RC-160-II possess prolonged and enhanced biological activities in suppressing serum GH and gastrin in rats. Significant variations in binding affinities for these analogs in different tissues and various tumors suggest that differences may exist between somatostatin receptors in normal versus malignant tissues. This raises the possibility that some of these analogs could be used more selectively in the treatment of various neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=0026593779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026593779&partnerID=8YFLogxK

M3 - Article

C2 - 1349189

AN - SCOPUS:0026593779

VL - 200

SP - 49

EP - 56

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

SN - 0037-9727

IS - 1

ER -